No Data
BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble
BriaCell Therapeutics (BCTX) shares were slumping about 10% in recent US trading on Wednesday after the immunotherapy company said it priced a private placement of slightly more than 2.4 million of it
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting
BriaCell Therapeutics (BCT.TO), which is developing immunotherapies to treat cancer, said it will make a presentation on the clinical data of the randomized Phase 2 study evaluating Bria-IMT in patien
BriaCell Announces Oral and Poster Presentations at ASCO 2024
Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster presentations include Drs. Hurvitz (Fred Hutchinson Cancer Center), Brufsky (UPMC), and Cristofanilli (Weill Cornell)
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+ and Bria-PROS+ Clinical Candidates for Breast and Prostate Cancer
Preclinical data shows that BriaCell's Bria-OTS+ and Bria-PROS+ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, a
BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR
BriaCell Therapeutics (BCT.TO), a clinical-stage biotechnology company, is presenting positive clinical data from its lead product candidate, Bria-IMT, in two of its three poster sessions during the 2